linjc16/ctgov huggingface dataset:
Thermal Imaging for Evaluation of the Cervix

Study Overview
=================
Brief Summary
-----------------
When screening results for cervical premalignant lesions are positive, colposcopy is recommended. This is highly sensitive screening method. However, specificity of the test is of low. Thus, a technology that improves the accuracy of the colposcopic exam is needed. This is a feasibility study with the goal of examining the performance of a thermal imaging camera in the detection of cervical malignant and premalignant lesions.

Official Title
-----------------
Thermal Imaging for Cervical Cancer Screening and Early Detection

Conditions
-----------------
Cervical Neoplasia

Intervention / Treatment
-----------------
* Device: Thermal imaging


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age > 18 Women with premalignant cervical lesions who are candidates for conization (group A) Women with a normal cervix who are candidates for hysterectomy (group B) Women with newly diagnosed cervical cancer Exclusion Criteria: For group A and B - women that had conization in the past

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: experimental<br>3 groups of patients will be participated: women with cancer, women with premalignant lesions and women with a normal cervix. All patients will undergo the same examination | Device: Thermal imaging<br>* Examination of the cervix by thermal imaging camera<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The rate of identification of premalignant and malignant lesions of the cervix by thermal imaging |  | 2 years |
Cognitive and Neurophysiological Effects of Raloxifene in Alzheimer's Disease

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to determine the effectiveness of treatment with raloxifene, an estrogen-like medication approved by the Food and Drug Administration for the treatment of osteoporosis, in improving memory and the ability to live independently in postmenopausal women with Alzheimer's disease.

Detailed Description
-----------------
The aim of this study is to determine the effectiveness of treatment with raloxifene, an estrogen-like medication (classified as Selective Estrogen Receptor Modulators (SER's)) approved by the Food and Drug Administration for the treatment of osteoporosis, in improving memory and the ability to live independently in postmenopausal women with Alzheimer's disease. Patients who volunteer for this study will need to visit the clinic 7 times (participate) over a period of five months and will receive either raloxifene or a harmless, inactive pill called a placebo. Neither the volunteers nor the study staff will know which type of pill a patient receives. Patients must be generally healthy and have mild-to-moderate dementia. There must be a patient caregiver who can watch for side effects and ensure that the patient takes the study pills on schedule over a period of three months. Patients will undergo neuropsychological tests and an evaluation of the ability to live independently at each visit as well as laboratory evaluations, such as the taking of blood. Each visit will last approximately 3 hours. A total of 20 patients is being recruited to participate in this study at the University of Wisconsin.

Official Title
-----------------
Cognitive and Neurophysiological Effects of Raloxifene in Alzheimer's Disease

Conditions
-----------------
Alzheimer Disease

Intervention / Treatment
-----------------
* Drug: Raloxifene


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Postmenopausal women with Alzheimer's disease and without other dementias (diagnosed by study staff or from an outside clinic) Mini Mental Status Exam score greater than 15/30 Exclusion Criteria: History of deep vein thrombosis or blot clots Diabetes Active heart disease or stroke Liver problems including hepatitis Severe vision or hearing problems Tobacco use

Ages Eligible for Study
-----------------
Minimum Age: 55 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Raloxifene|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Alzheimer disease, Postmenopausal women, Hormone therapy
Gait Analysis in Females Suffering From Patellofemoral Pain Syndrome (PFPS)

Study Overview
=================
Brief Summary
-----------------
The purpose of the study was to evaluate the spatial and temporal variables during walking cycle in adolescent females suffering from patellofemoral pain syndrome (PFPS) versus healthy adolescent females .

Official Title
-----------------
Gait Analysis in Females Suffering From Patellofemoral Pain Syndrome (PFPS)

Conditions
-----------------
Patellofemoral Pain Syndrome

Intervention / Treatment
-----------------
* Other: gait assessment


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: peripatellar or retropatellar knee pain worsen with upstairs and walking Exclusion Criteria: previous knee or patella surgeries

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
Female

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| group A<br>Group A (Study group ) : 25 adolescent females suffering patellofemoral pain syndrome were recruited from the outpatient clinic of the faculty of physical therapy delta university in addition to the medical diagnosis was confirmed by consultant orthopedist using clinical and radiographic investigations . | Other: gait assessment<br>* gait assessment were done using 3DMA system<br>|
| group B<br>Group B (Control Group):25 adolescent females with healthy knee joints with no clinical and radiographic evidence of patellofemoral pain syndrome , were recruited from the students of the faculty of physical therapy delta university . | Other: gait assessment<br>* gait assessment were done using 3DMA system<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| step length | measured during gait cycle in adolescent females suffering patellofemoral pain syndrome (PFPS) versus healthy adolescent females was done in motion analysis lab in Delta University for Science & Technology which equipped with walkway and six infrared cameras operating at 60 HZ frequency. | 3 months | 
| stride length | measured during gait cycle in adolescent females suffering patellofemoral pain syndrome (PFPS) versus healthy adolescent females was done in motion analysis lab in Delta University for Science & Technology which equipped with walkway and six infrared cameras operating at 60 HZ frequency. | 3 months | 
| speed | measured during gait cycle in adolescent females suffering patellofemoral pain syndrome (PFPS) versus healthy adolescent females was done in motion analysis lab in Delta University for Science & Technology which equipped with walkway and six infrared cameras operating at 60 HZ frequency. | 3 months |
Clinical Evaluation of Bacitracin

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to establish a concentration of a bacitracin-patch for diagnosing allergic contact dermatitis.

Detailed Description
-----------------
Thin-layer Rapid Use Epicutaneous Test (T.R.U.E. Test®) is a ready-to-use patch test method designed for diagnosis of allergic contact dermatitis. The standard panel consists of two tape strips, panel 1, with 11 allergen patches and a negative control and panel 2, with 12 allergen patches. T.R.U.E. TestTM panels 1 and 2 contain 23 of the most frequent contact allergens. With the 23 allergens the test currently consists of, it is possible to detect about 60-70% of contact allergic reactions. Thus, there is a need for expanding the number of allergens included in T.R.U.E.Test in order to detect more contact allergic reactions. Bacitracin is one of these allergens, and the purpose of this study is to determine a concentration for the patch by using a bacitracin dilution series.

Official Title
-----------------
Clinical Evaluation of Bacitracin. A Phase II Dose-Response Study

Conditions
-----------------
Allergic Contact Dermatitis

Intervention / Treatment
-----------------
* Drug: bacitracin (allergen)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Positive bacitracin patch test within the latest 5 years. Age greater than or equal to 18 years. Signed informed consent. Exclusion Criteria: Topical treatment with corticosteroids or immunosuppressives during the latest 7 days on the test area or near the test area. Systemic treatment with corticosteroids or immunosuppressives during the latest 7 days. Treatment with ultraviolet (UV)-light during the latest 3 weeks. Widespread active dermatitis or dermatitis on test area. Breast-feeding or pregnancy. Females of childbearing potential must demonstrate a negative pregnancy test before inclusion in the study. Subjects not able to cooperate.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: bacitracin (allergen)|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Skin reaction to the patch test after 72-96 hours and after 7 days |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluation of safety including late and persistent responses |  |  | 
| Evaluation day 3/4, day 7 and day 21 |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Allergic contact dermatitis, Patch testing, bacitracin
Ocular Pressure in Steroid-treated Dermatology Patients

Study Overview
=================
Brief Summary
-----------------
Ocular hypertension and glaucoma are eye conditions associated with abnormally high fluid pressure in the eye (called intraocular pressure or IOP). If left untreated, the elevated IOP may eventually cause damage to the nerve of the eye and potential impairment of vision. The use of certain drugs has been identified as a risk factor for raised IOP, including various forms of administration of corticosteroids. Corticosteroids can also lead to cataract, which is clouding of the lens in the eye that can affect vision. In this research study, we would like to find out whether the use of corticosteroids in our dermatology clinic leads to raised IOP, in order to identify patients at risk and to allow them to be more closely monitored than others. It is important to identify those patients who have a corticosteroid-induced pressure rise early enough to prevent them from permanent glaucomatous visual loss.

Official Title
-----------------
Intraocular Pressure in Corticosteroid-treated Dermatology Patients

Conditions
-----------------
Topical Corticosteroid-treated Dermatology Patients, Intra-ocular Pressure

Intervention / Treatment
-----------------
* Drug: Potent topical steroid
* Drug: Superpotent topical steroid


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients on whom corticosteroid treatment is being introduced for a duration of at least 12 weeks Exclusion Criteria: pregnant women patients already under glaucoma treatment patients unable to give informed written consent or those unable to cooperate fully with the assessments

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Potent topical steroid-treated<br>Patients treated with potent topical steroids | Drug: Potent topical steroid<br> <br> |
| Superpotent topical steroid-treated<br>Patients treated with superpotent topical steroids | Drug: Superpotent topical steroid<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in intraocular pressure from baseline | Measurements will be done at 28 (+/- 7 days) days, 56 (+/- 7 days) days, and 90 (+/- 7 days)days after initiation of topical steroids. | after 1, 2 and 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Whether there is any clinical evidence of cataract at the final visit of the study. | Measurements will be done at 28 (+/- 7 days) days, 56 (+/- 7 days) days, and 90 (+/- 7 days)days after initiation of topical steroids. | After 1, 2 and 3 months |
Language Acquisition in the Brain and Algorithms: Towards Systematic Monitoring of the Evolution of Semantic Representations in Biological and Artificial Neural Networks

Study Overview
=================
Brief Summary
-----------------
Speech depends on our ability to recursively combine successive words into a complex sense. Although the order of these putative operations (syntax) has been the subject of extensive examination in the way in which the human brain learns to perform a Semantic composition remains largely unknown. The Rothschild Hospital houses a unit specializing in drug-resistant epilepsy in children from 2 to 20 years old. The identification of the epileptogenic zone often requires making an iEEG recording for a week (implantation of intracerebral electrodes in depth). Sometimes this recording has to be repeated, providing a unique opportunity to directly record brain activity at different periods of its development. Children will listen to pre-recorded phrases and stories such as The Little Prince of Antoine de Saint-Exupéry while being recorded with iEEG.

Official Title
-----------------
Language Acquisition in the Brain and Algorithms: Towards Systematic Monitoring of the Evolution of Semantic Representations in Biological and Artificial Neural Networks

Conditions
-----------------
Language Acquisition in the Brain

Intervention / Treatment
-----------------
* Other: intracranial brain recording


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Any patient benefiting from a long-term intracranial brain recording. Non-opposition to participating in the study (adult patients) Non-opposition of at least one of the holders of the exercise of parental authority (minor patients) Exclusion Criteria: Patient with complete deafness

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: intracranial brain recording|Any patient benefiting from a long-term intracranial brain recording.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| This is a non-clinical research study investigating from intracranial recordings how speech representation changes throughout human development. | intracranial recordings | maximum 21 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Intracranial recordings
Safety, Tolerability, Pharmacokinetics and -Dynamics of Multiple Rising Oral Doses of BI 113823 in Patients Patients With Osteoarthritis of the Knee

Study Overview
=================
Brief Summary
-----------------
The objective of the study is to investigate the safety and tolerability of BI 113823 in male and female patients with osteoarthritis, following oral administration of BI 113823 with repeated rising doses.

Official Title
-----------------
Safety, Tolerability, Pharmacokinetics and Pharmacodynamic of Multiple Rising Oral Doses (50, 100, 200 and 350 mg qd and 100 mg Bid for 12 Days) of BI 113823 as Tablet in Male and Female Patients With Osteoarthritis of the Knee (Randomised, Double-blind, Placebo-controlled Within the Dose Groups, Clinical Phase I)

Conditions
-----------------
Osteoarthritis

Intervention / Treatment
-----------------
* Drug: BI 113823


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria patients with osteoarthritis Exclusion criteria

Ages Eligible for Study
-----------------
Minimum Age: 35 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: BI 113823<br>5 dose-groups of multiple oral doses of BI 113823 | Drug: BI 113823<br>* 5 dose-groups of multiple oral doses of BI 113823<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety (Physical examination) |  | 15 days | 
| Safety (Vital signs) |  | 15 days | 
| Safety (12-lead ECG) |  | 15 days | 
| Safety (Clinical laboratory tests) |  | 15 days | 
| Safety (Adverse Events) |  | 15 days | 
| Tolerability (Assessment of tolerability by investigator) |  | 15 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Measures of pharmacodynamic effects |  | 15 days | 
| Standard pharmacokinetic parameters for single dose and steady state conditions will be assessed |  | 15 days |
0.3% Sodium Hyaluronate in the Treatment of Dry Eye of Diabetic Patients

Study Overview
=================
Brief Summary
-----------------
A randomized parallel controlled study was designed to compare the efficacy of 0.3% Sodium Hyaluronate in the treatment of Dry Eye of diabetic patients.

Official Title
-----------------
0.3% Sodium Hyaluronate in the Treatment of Dry Eye of Diabetic Patients

Conditions
-----------------
Dry Eye Syndromes, Diabetes Mellitus

Intervention / Treatment
-----------------
* Drug: 0.3% Sodium Hyaluronate


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: medical history of diabetes diagnosed with proliferative diabetic retinopathy diagnosed with dry eye not involvement in other drug experiment in the past 2 weeks vision acuity better than 0.1 no local drug using history or with at least 2 weeks blanking period Exclusion Criteria: allergy to any of the drug ingredient being or going to be pregnant or in lactation period with any other eye disease or other serious disease which might affect the trial or could not get in follow-up with any eye surgery history in the past six months usage of hormone for replacement therapy

Ages Eligible for Study
-----------------
Minimum Age: 17 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: treatment group<br>treatment with 0.3% Sodium Hyaluronate, by five times a day, one or two drop each time | Drug: 0.3% Sodium Hyaluronate<br>* five times per day for the intervention of eye drop<br>|
| No Intervention: control group<br>without treatment | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ocular surface disease index | pre-,1,4,8 weeks after the initiation of the study(the use of drug for experimental group) | up to 2 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| tear break up time | BUT | up to 2 months | 
| Schirmer' test | test of tear secretion | up to 2 months | 
| conjunctival goblet cells density | indirect assessment of tear quality | up to 2 months | 
| corneal fluorescein staining assessment | assessment of the corneal invasion | up to 2 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
dry eye syndromes, diabetes mellitus